A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT05379595

Public ClinicalTrials.gov record NCT05379595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Study identification

NCT ID: NCT05379595
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Advanced or Metastatic Colorectal Cancer

Interventions

Amivantamab Biological
Amivantamab IV Biological
Fluorouracil Biological
Irinotecan Biological
Leucovorin Biological
Oxaliplatin Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2022
Primary completion: Apr 26, 2027
Completion: Oct 30, 2030
Last update posted: May 7, 2026

2022 – 2030

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
O Neal Comprehensive Cancer Center at UAB	Birmingham	Alabama	35233	Recruiting
University of Southern California	Los Angeles	California	90033	Completed
University of California, Los Angeles UCLA	Los Angeles	California	90404	Recruiting
Georgetown University Hospital	Washington D.C.	District of Columbia	20007	Recruiting
H Lee Moffitt Cancer Center	Tampa	Florida	33612	Completed
University of Maryland School of Medicine	Baltimore	Maryland	21201	Completed
University of Michigan Health System	Ann Arbor	Michigan	48103	Recruiting
Start Midwest	Grand Rapids	Michigan	49546	Recruiting
Hattiesburg Clinic	Hattiesburg	Mississippi	39401	Recruiting
NYU Langone Long Island Clinical Research Associates	New York	New York	10016	Recruiting
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center	New York	New York	10032	Recruiting
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
Vanderbilt Ingram Cancer Center	Nashville	Tennessee	37232	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05379595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05379595 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →